Geneos Wealth Management’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Geneos Wealth Management’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3	Closed	-$1K	–	2901
2020 Q3	$1K	Buy	+3	New	+$1.25K	﹤0.01%	2492

Other funds holding CANF

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Geneos Wealth Management's CANF Position: Q4 2020 in Review

Geneos Wealth Management sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q4 2020, closing a stake of 3 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in CANF in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 6 funds tracked by Wall St. Rank hold CANF as of Q4 2020.

Geneos Wealth Management reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q4 2020 after selling out during the quarter.
Geneos Wealth Management sold 3 Can-Fite BioPharma American Depositary Shares shares in Q4 2020, an estimated $1K.
Geneos Wealth Management first reported a position in Can-Fite BioPharma American Depositary Shares in Q3 2020 and held it in 1 quarter.
Geneos Wealth Management's Can-Fite BioPharma American Depositary Shares position peaked at $1K in Q3 2020.
6 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q4 2020.

Based on Geneos Wealth Management's 13F filing for Q4 2020, filed 19 May 2021.